Cleared Traditional

SURGICAL BLADES & SCAPELS (SMPL. W/510K) (K812516) - FDA 510(k) Clearance

Class I General & Plastic Surgery device.

K812516 · Needle Industries(Usa), Inc. · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1981
Decision
30d
Days
Class 1
Risk

K812516 is an FDA 510(k) clearance for the SURGICAL BLADES & SCAPELS (SMPL. W/510K). Classified as Blade, Scalpel (product code GES), Class I - General Controls.

Submitted by Needle Industries(Usa), Inc. (Mchenry, US). The FDA issued a Cleared decision on October 2, 1981 after a review of 30 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4800 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Needle Industries(Usa), Inc. devices

Submission Details

510(k) Number K812516 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 02, 1981
Decision Date October 02, 1981
Days to Decision 30 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
85d faster than avg
Panel avg: 115d · This submission: 30d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GES Blade, Scalpel
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4800
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.